Summary
Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Severe Acute Respiratory Syndrome (SARS) - Drugs In Development, 2022, provides an overview of the Severe Acute Respiratory Syndrome (SARS) (Infectious Disease) pipeline landscape.
Severe acute respiratory syndrome (SARS) is a serious, potentially life-threatening viral infection caused by virus from the Coronaviridae family. Symptoms include cough, chills and shaking, headache, muscle aches, diarrhea, dizziness, nausea and vomiting. Risk factors include gene variation in the immune system and close contact with someone who has SARS.
Report Highlights
Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Severe Acute Respiratory Syndrome (SARS) - Drugs In Development, 2022, provides comprehensive information on the therapeutics under development for Severe Acute Respiratory Syndrome (SARS) (Infectious Disease), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.
The Severe Acute Respiratory Syndrome (SARS) (Infectious Disease) pipeline guide also reviews of key players involved in therapeutic development for Severe Acute Respiratory Syndrome (SARS) and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Phase II, Phase I, Preclinical and Discovery stages are 3, 1, 17 and 16 respectively. Similarly, the Universities portfolio in Preclinical and Discovery stages comprises 4 and 1 molecules, respectively.
Severe Acute Respiratory Syndrome (SARS) (Infectious Disease) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.
Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.
Scope
- The pipeline guide provides a snapshot of the global therapeutic landscape of Severe Acute Respiratory Syndrome (SARS) (Infectious Disease).
- The pipeline guide reviews pipeline therapeutics for Severe Acute Respiratory Syndrome (SARS) (Infectious Disease) by companies and universities/research institutes based on information derived from company and industry-specific sources.
- The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
- The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
- The pipeline guide reviews key companies involved in Severe Acute Respiratory Syndrome (SARS) (Infectious Disease) therapeutics and enlists all their major and minor projects.
- The pipeline guide evaluates Severe Acute Respiratory Syndrome (SARS) (Infectious Disease) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
- The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
- The pipeline guide reviews latest news related to pipeline therapeutics for Severe Acute Respiratory Syndrome (SARS) (Infectious Disease)
Reasons to Buy
- Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
- Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
- Find and recognize significant and varied types of therapeutics under development for Severe Acute Respiratory Syndrome (SARS) (Infectious Disease).
- Classify potential new clients or partners in the target demographic.
- Develop tactical initiatives by understanding the focus areas of leading companies.
- Plan mergers and acquisitions meritoriously by identifying key players and it’s most promising pipeline therapeutics.
- Formulate corrective measures for pipeline projects by understanding Severe Acute Respiratory Syndrome (SARS) (Infectious Disease) pipeline depth and focus of Indication therapeutics.
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
- Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.
'
Table of Contents
List of Tables
List of Figures
Introduction
Global Markets Direct Report Coverage
Severe Acute Respiratory Syndrome (SARS) - Overview
Severe Acute Respiratory Syndrome (SARS) - Therapeutics Development
Pipeline Overview
Pipeline by Companies
Pipeline by Universities/Institutes
Products under Development by Companies
Products under Development by Universities/Institutes
Severe Acute Respiratory Syndrome (SARS) - Therapeutics Assessment
Assessment by Target
Assessment by Mechanism of Action
Assessment by Route of Administration
Assessment by Molecule Type
Severe Acute Respiratory Syndrome (SARS) - Companies Involved in Therapeutics Development
Severe Acute Respiratory Syndrome (SARS) - Drug Profiles
Severe Acute Respiratory Syndrome (SARS) - Dormant Projects
Severe Acute Respiratory Syndrome (SARS) - Product Development Milestones
Featured News & Press Releases
Apr 05, 2022: VBI Vaccines provides new data on VBI-2901
Mar 31, 2022: Adagio’s antibody meets primary endpoints in Phase II/III Covid-19 trials
Mar 17, 2022: BioVaxys announces bioproduction of BVX-1021 for its pan-sarbecovirus program in collaboration with The Ohio State University
Mar 01, 2022: Study finds MK-4482 inhibits replication of multiple SARS-CoV-2 variants of concern in Syrian hamster COVID-19 model
Dec 22, 2021: Cocrystal Pharma’s COVID-19 oral and intranasal/pulmonary protease inhibitors exhibit powerful in vitro potency against the SARS-CoV-2 Omicron variant
Dec 16, 2021: Merck and Ridgeback announce publication of phase 3 study of Molnupiravir, an investigational oral antiviral COVID-19 treatment, in the New England Journal of Medicine
Oct 04, 2021: Merck-Ridgeback’s oral drug lowers hospitalisation risk in Covid-19 trial
Sep 30, 2021: Adagio’s ADG20 demonstrates benefit in Covid-19 clinical programme
Sep 24, 2021: A new oral antiviral drug for COVID is being tested in humans
Jul 26, 2021: Announcement of the effect of OBP-2011 against Indian and South African variants of SARS-CoV-2 virus
Jul 19, 2021: Announcement of manufacturing partnership on OBP-2011, an investigational product for COVID-19
Jun 21, 2021: Starpharma provides update on VIRALEZE UK
Jun 14, 2021: Announcement of the effect of OBP-2011 against SARS and MERS
Jun 01, 2021: Scripps Research Institute testing shows Viraleze highly active against UK COVID strain
Apr 19, 2021: NIH study finds antiviral drug effective against Covid-19
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer
List of Tables
Number of Products under Development for Severe Acute Respiratory Syndrome (SARS), 2022
Number of Products under Development by Companies, 2022
Number of Products under Development by Companies, 2022 (Contd..1)
Number of Products under Development by Universities/Institutes, 2022
Products under Development by Companies, 2022
Products under Development by Companies, 2022 (Contd..1)
Products under Development by Universities/Institutes, 2022
Number of Products by Stage and Target, 2022
Number of Products by Stage and Mechanism of Action, 2022
Number of Products by Stage and Route of Administration, 2022
Number of Products by Stage and Molecule Type, 2022
Severe Acute Respiratory Syndrome (SARS) - Pipeline by Adagio Therapeutics Inc, 2022
Severe Acute Respiratory Syndrome (SARS) - Pipeline by AIkido Pharma Inc, 2022
Severe Acute Respiratory Syndrome (SARS) - Pipeline by AlphaVax Inc, 2022
Severe Acute Respiratory Syndrome (SARS) - Pipeline by Amide Technologies Inc, 2022
Severe Acute Respiratory Syndrome (SARS) - Pipeline by Autoimmune Technologies LLC, 2022
Severe Acute Respiratory Syndrome (SARS) - Pipeline by Biotron Ltd, 2022
Severe Acute Respiratory Syndrome (SARS) - Pipeline by BioVaxys Technology Corp, 2022
Severe Acute Respiratory Syndrome (SARS) - Pipeline by Calder Biosciences Inc, 2022
Severe Acute Respiratory Syndrome (SARS) - Pipeline by Cidara Therapeutics Inc, 2022
Severe Acute Respiratory Syndrome (SARS) - Pipeline by Citospin SL, 2022
Severe Acute Respiratory Syndrome (SARS) - Pipeline by Cloud Pharmaceuticals Inc, 2022
Severe Acute Respiratory Syndrome (SARS) - Pipeline by Cocrystal Pharma Inc, 2022
Severe Acute Respiratory Syndrome (SARS) - Pipeline by ConserV Bioscience Ltd, 2022
Severe Acute Respiratory Syndrome (SARS) - Pipeline by CSL Ltd, 2022
Severe Acute Respiratory Syndrome (SARS) - Pipeline by Fab’entech SA, 2022
Severe Acute Respiratory Syndrome (SARS) - Pipeline by Global BioLife Inc Ltd, 2022
Severe Acute Respiratory Syndrome (SARS) - Pipeline by Halo Therapeutics Ltd, 2022
Severe Acute Respiratory Syndrome (SARS) - Pipeline by Hinge Bio Inc, 2022
Severe Acute Respiratory Syndrome (SARS) - Pipeline by Immodulon Therapeutics Ltd, 2022
Severe Acute Respiratory Syndrome (SARS) - Pipeline by Immune Biosolutions Inc, 2022
Severe Acute Respiratory Syndrome (SARS) - Pipeline by Lattice Biologics Ltd, 2022
Severe Acute Respiratory Syndrome (SARS) - Pipeline by Merck & Co Inc, 2022
Severe Acute Respiratory Syndrome (SARS) - Pipeline by Merck KGaA, 2022
Severe Acute Respiratory Syndrome (SARS) - Pipeline by Novavax Inc, 2022
Severe Acute Respiratory Syndrome (SARS) - Pipeline by Oncolys BioPharma Inc, 2022
Severe Acute Respiratory Syndrome (SARS) - Pipeline by Oncovir Inc, 2022
Severe Acute Respiratory Syndrome (SARS) - Pipeline by Phelix Therapeutics LLC, 2022
Severe Acute Respiratory Syndrome (SARS) - Pipeline by Pulmotect Inc, 2022
Severe Acute Respiratory Syndrome (SARS) - Pipeline by Sagimet Biosciences Inc, 2022
Severe Acute Respiratory Syndrome (SARS) - Pipeline by Sorrento Therapeutics Inc, 2022
Severe Acute Respiratory Syndrome (SARS) - Pipeline by Starpharma Holdings Ltd, 2022
Severe Acute Respiratory Syndrome (SARS) - Pipeline by Theravectys SA, 2022
Severe Acute Respiratory Syndrome (SARS) - Pipeline by Trimunocor Ltd, 2022
Severe Acute Respiratory Syndrome (SARS) - Pipeline by Valo Therapeutics Oy, 2022
Severe Acute Respiratory Syndrome (SARS) - Pipeline by VBI Vaccines Inc, 2022
Severe Acute Respiratory Syndrome (SARS) - Dormant Projects, 2022
Severe Acute Respiratory Syndrome (SARS) - Dormant Projects, 2022 (Contd..1)
List of Figures
Number of Products under Development for Severe Acute Respiratory Syndrome (SARS), 2022
Number of Products under Development by Companies, 2022
Number of Products under Development by Universities/Institutes, 2022
Number of Products by Top 10 Targets, 2022
Number of Products by Stage and Top 10 Targets, 2022
Number of Products by Top 10 Mechanism of Actions, 2022
Number of Products by Stage and Top 10 Mechanism of Actions, 2022
Number of Products by Top 10 Routes of Administration, 2022
Number of Products by Stage and Top 10 Routes of Administration, 2022
Number of Products by Top 10 Molecule Types, 2022
Number of Products by Stage and Top 10 Molecule Types, 2022
